A Phase II Trial and Pharmacokinetic Study of Oxaliplatin in Children With Refractory Solid Tumors: A Children's Oncology Group Study
A Phase II Trial and Pharmacokinetic Study of Oxaliplatin in Children With Refractory Solid Tumors: A Children's Oncology Group Study
复制标题
DOI：
10.1002/pbc.22544
复制
发表时间：
2010-09-01
影响因子：
3.2
通讯作者：
Adamson, Peter C.
中科院分区：
文献类型：
--
作者：
Beaty, Orren, III;Berg, Stacey;Adamson, Peter C.
背景。铂剂用于治疗一系列儿童癌症。奥沙利铂是第三代铂化合物，毒性较小且更有效。进行了一项 2 期研究，以评估难治性儿科实体瘤患者对单药奥沙利铂的反应率，并进一步描述该药物在该人群中的毒性和药代动力学。患者和方法。科目，
Background. Platinating agents are used in the treatment of a spectrum of childhood cancers. Oxaliplatin, a third generation platinum compound, may provide less toxicity and be more effective. A phase 2 study was performed to estimate the response rate to single agent oxaliplatin in patients with refractory pediatric solid tumors, and to further describe the toxicities and pharmacokinetics of the drug in this population. Patients and Methods. Subjects,